Anti-C5a antibody vilobelimab treatment and the effect on biomarkers of inflammation and coagulation in patients with severe COVID-19 › Research Explorer

DOI

https://doi.org/10.1186/s12931-022-02278-1
Final published version

Original language	English
Article number	375
Number of pages	6
Journal	Respiratory research
Volume	23
Issue number	1
DOIs	https://doi.org/10.1186/s12931-022-02278-1
Publication status	Published - 1 Dec 2022

Research areas

C5a, COVID-19, Complement, Complement inhibition, SARS-CoV-2, Vilobelimab

ID: 29085632